Breaking News, Financial News

Financial Report: Hospira

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira

2Q Revenues: $671 million (+1%)

2Q Earnings: $54 million (-25%)

YTD Revenues: $1.3 billion (+1%)

YTD Earnings: $134 million (-10%)

Comments: R&D expense rose 19% percent in the quarter to $39 million. S,G&A expense in the quarter was $111 million, or 17% of sales, compared with $87 million, or 13% of sales in 2Q2005. The company completed its legal separation from Abbott in the quarter, including the transition of the remaining countries to Hospira.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters